Table 2 Effect of test compounds (5a–e) and rosiglitazone on the FBG of STZ-induced diabetic mice.

From: Synthesis, molecular docking, and in vivo antidiabetic evaluation of new benzylidene-2,4-thiazolidinediones as partial PPAR-γ agonists

Group

FBG (mg/dL)

% change (Day 21–Day 0)

Day 0

Day 7

Day 14

Day 21

Diabetic control

265.7 ± 17.2

302.9 ± 18.9

319.9 ± 24

345.7 ± 12.4

30.1 ± 13.4

Rosiglitazone

269.7 ± 2.1

191.0 ± 9.5****

161.7 ± 7.8****

130.7 ± 1.5****

51.5 ± 0.7

5a

287.0 ± 6.1*

195.7 ± 7.0****

167.0 ± 3.6****

132.3 ± 5.5****

53.9 ± 1.7

5b

273.3 ± 6.8

206.0 ± 14.7****

174.3 ± 10.2****

125 ± 6.6****

54.2 ± 3.0

5c

272.3 ± 16.9

210.0 ± 15.7****

164 ± 19.1****

124.3 ± 5.7****

54.4 ± 4.8

5d

298 ± 14**

194.3 ± 5.0****

158.7 ± 9.5****

121.3 ± 4.5****

59.3 ± 1.8

5e

285.0 ± 8.5

207.3 ± 16.8****

169.0 ± 2.7****

126.3 ± 5.5****

55.7 ± 1.0

  1. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Back to article page